BioLine RX Financials
| BLRX Stock | ILS 1.60 0.10 6.67% |
BioLine |
Understanding current and past BioLine RX Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of BioLine RX's financial statements are interrelated, with each one affecting the others. For example, an increase in BioLine RX's assets may result in an increase in income on the income statement.
Please note, the presentation of BioLine RX's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, BioLine RX's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of BioLine RX's management manipulating its earnings.
BioLine RX Stock Summary
BioLine RX competes with Can Fite, Clal Biotechnology, Evogene, XTL Biopharmaceutica, and Together Startup. BioLineRx Ltd., a clinical stage biopharmaceutical development company, focuses on oncology and immunology. BioLineRx Ltd. was founded in 2003 and is based in Modiin, Israel. BIOLINE RX operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 48 people.| Foreign Associate | USA |
| Instrument | Israel Stock View All |
| Exchange | Tel Aviv Stock Exchange |
| ISIN | IL0011015182 |
| Business Address | 2 HaMaayan Street, |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.biolinerx.com |
| Phone | (972) 8 642 9101 |
| Currency | ILS - Israeli Shekel |
You should never invest in BioLine RX without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of BioLine Stock, because this is throwing your money away. Analyzing the key information contained in BioLine RX's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
BioLine RX Key Financial Ratios
BioLine RX's financial ratios allow both analysts and investors to convert raw data from BioLine RX's financial statements into concise, actionable information that can be used to evaluate the performance of BioLine RX over time and compare it to other companies across industries.BioLine Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining BioLine RX's current stock value. Our valuation model uses many indicators to compare BioLine RX value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across BioLine RX competition to find correlations between indicators driving BioLine RX's intrinsic value. More Info.BioLine RX is rated fourth in return on equity category among its peers. It is rated third in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value BioLine RX by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for BioLine RX's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.BioLine RX January 11, 2026 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of BioLine RX help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of BioLine RX. We use our internally-developed statistical techniques to arrive at the intrinsic value of BioLine RX based on widely used predictive technical indicators. In general, we focus on analyzing BioLine Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build BioLine RX's daily price indicators and compare them against related drivers.
| Information Ratio | (0.12) | |||
| Maximum Drawdown | 18.01 | |||
| Value At Risk | (5.88) | |||
| Potential Upside | 6.67 |
Complementary Tools for BioLine Stock analysis
When running BioLine RX's price analysis, check to measure BioLine RX's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioLine RX is operating at the current time. Most of BioLine RX's value examination focuses on studying past and present price action to predict the probability of BioLine RX's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioLine RX's price. Additionally, you may evaluate how the addition of BioLine RX to your portfolios can decrease your overall portfolio volatility.
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm |